This article is more than 5 years old. Information may no longer be current.

AOSPINE North America enrolls 50th patient for spinal cord injury trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

AOSPINE North America has enrolled 50 patients for a clinical trial on the efficacy and safety of riluzole for patients with acute spinal cord injury, according to a press release.

Riluzole is FDA approved for the treatment of amyotrophic lateral sclerosis. The level 1 study will assess whether the treatment will improve recovery following spinal cord injury compared with placebo. The early-stage trial reportedly indicated riluzole as safe and well tolerated in patients in an acute setting.

The trial reportedly is the largest spinal cord injury clinical research effort and includes more than 20 top-ranked Australian, Canadian and American universities. The research is funded by the AO Foundation, the U.S. government, Christopher and Dana Reeve Foundation, Ontario Neurotrauma Foundation and Rick Hansen Institute, according to the release. Leaders of the study include Michael G. Fehlings, MD, PhD, professor and vice-chairman of neurosurgery at the University of Toronto, and Robert Grossman, MD, professor of neurosurgery at the Institute for Academic Medicine at Houston Methodist Hospital.

Reference:

www.aospine.aofoundation.org